Amgen Inc.

• 

  Supreme Court Backs 5-Year Limit on Securities Fraud Cases

  By Melanie Waddell, AdvisorOne  |  February 27, 2013

  The Supreme Court issued two rulings on Wednesday: one stating that the SEC must bring securities fraud cases within five years of when the fraud occurred, and another making it easier for shareholders to bring class-action lawsuits.

• 

  Top 8 Most Overpaid CEOs of Public Companies

  By Marlene Y. Satter, AdvisorOne  |  November 2, 2011

  Some CEOs keep raking in the bucks even as the companies they lead lose market share, see their stock price fall, or both.

• Fund in Focus: Permanent Aggressive Growth Portfolio

  By Staff Writer  |  July 21, 2005

  Michael J. Cuggino, manager since January 1991 S&P Rank: 4 Stars Aggressive Growth Fund Takes The Long View

• Fund in Focus: Constellation Sands Capital Select Growth

  By Staff Writer  |  August 18, 2004

  Frank Sands Jr., manager since July 2000 S&P Rank: 3 Stars Bulking Up On Biotech

• Evan McCulloch of Franklin Biotechnology Discovery Fund

  By Staff Writer  |  March 24, 2004

  S&P Rank: 3 Stars March 11, 2004 Biotechs High on Drug Approvals

• Liu-Er Chen of Evergreen Health Care Fund

  By Staff Writer  |  August 25, 2003

  S&P Rank: 4 Stars Aug. 14, 2003 On the Cusp of a New Drug Boom Quick Take: Drug and biotech stocks suffered in 2002, hurt by poor earnings,...

• Evan McCulloch of Franklin Biotechnology Discovery

  By Staff Writer  |  February 10, 2003

  S&P Rank: 3 Stars Strong Dose of Biotech